Pleiotropic Protective Effects of Progranulin in the Treatment of Ischemic Stroke
Stroke is one of the leading causes of morbidity and mortality in the world. The majority of strokes is ischemic. Unfortunately, there is still not well substantial treatment option to increase the survival and alleviate the outcome after ischemic stroke. In the central nervous system, progranulin (PGRN) is considered to play important roles in the maintenance of physiological functions. Mutations in the gene that encodes PGRN cause transactive response DNA-binding protein 43-positive frontotemporal lobar degeneration. Several studies have reported that PGRN exerts protective effects against ischemic brain injury. PGRN alleviates the impairments after acute focal cerebral ischemia by a variety of mechanisms, which we call “brain protection”. This includes neuroprotection, suppression of neuroinflammation, and attenuation of blood-brain barrier disruption, i.e., vascular protection. PGRN has pleiotropic protective effects and is, therefore, an ideal candidate molecule for the therapy of stroke. We will accelerate the research towards further development of PGRN-based treatments of stroke.
KeywordsCerebral ischemia Tissue plasminogen activator Brain protection Pleiotropic protective effects
- Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al (2016) American Heart Association Statistics Committee; stroke statistics subcommittee. Executive summary: heart disease and stroke Statistics-2016 update: a report from the American Heart Association. Circulation 133:447–454CrossRefGoogle Scholar